EBITDA margin guidance of 27-29% for FY26
Management reiterated EBITDA margin guidance of 27-29% for FY26, with Q3 margin at 28.7%.
JBCHEPHARM / guidance tracker
Keep management guidance in view.
JB Chemicals & Pharmaceuticals · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
margins
Domestic business to grow 200-300 bps above IPM
Domestic business expected to outperform IPM by 200-300 bps, with Q3 growth of 10% vs IPM 9%.
International business to grow high single digit for FY26
International business expected to end FY26 with high single-digit growth, driven by strong order book in Q4.
CDMO business to grow 10-12% in FY27
CDMO segment expected to grow 10-12% in FY27, with current quarterly run rate of 115-120 Cr.